JOP20240240A1 - حمض نووي معزول يشفر بروتين اندماج قائم على fviii-bdd وعلى ببتيد إشارة غير متجانس - Google Patents

حمض نووي معزول يشفر بروتين اندماج قائم على fviii-bdd وعلى ببتيد إشارة غير متجانس

Info

Publication number
JOP20240240A1
JOP20240240A1 JOJO/P/2024/0240A JOP20240240A JOP20240240A1 JO P20240240 A1 JOP20240240 A1 JO P20240240A1 JO P20240240 A JOP20240240 A JO P20240240A JO P20240240 A1 JOP20240240 A1 JO P20240240A1
Authority
JO
Jordan
Prior art keywords
bdd
fviii
fusion protein
signal peptide
based fusion
Prior art date
Application number
JOJO/P/2024/0240A
Other languages
Arabic (ar)
English (en)
Inventor
Mariya Pavlovna Perepelkina
Pavel Mikhailovich Gershovich
Stock Company Biocad Joint
Elena Veniaminovna Vlasova
Anastasiia Vladimirovna Fomina
Vitaliia Aleksandrovna Markova
Dmitry Valentinovich Morozov
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2022111695A external-priority patent/RU2818229C2/ru
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of JOP20240240A1 publication Critical patent/JOP20240240A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JOJO/P/2024/0240A 2022-04-28 2024-10-27 حمض نووي معزول يشفر بروتين اندماج قائم على fviii-bdd وعلى ببتيد إشارة غير متجانس JOP20240240A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2022111695A RU2818229C2 (ru) 2022-04-28 Выделенная нуклеиновая кислота, которая кодирует слитый белок на основе FVIII-BDD и гетерологичного сигнального пептида, и ее применение
PCT/RU2023/050093 WO2023211315A1 (en) 2022-04-28 2023-04-18 Isolated nucleic acid that encodes fusion protein based on fviii-bdd and on heterologous signal peptide

Publications (1)

Publication Number Publication Date
JOP20240240A1 true JOP20240240A1 (ar) 2024-10-27

Family

ID=88519415

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2024/0240A JOP20240240A1 (ar) 2022-04-28 2024-10-27 حمض نووي معزول يشفر بروتين اندماج قائم على fviii-bdd وعلى ببتيد إشارة غير متجانس

Country Status (19)

Country Link
EP (1) EP4514975A1 (https=)
JP (1) JP2025515356A (https=)
KR (1) KR20250005425A (https=)
CN (1) CN117402901A (https=)
AR (1) AR129164A1 (https=)
AU (1) AU2023261711A1 (https=)
CA (1) CA3250663A1 (https=)
CL (1) CL2024003295A1 (https=)
CO (1) CO2024014703A2 (https=)
CR (1) CR20240525A (https=)
IL (1) IL316578A (https=)
JO (1) JOP20240240A1 (https=)
MA (1) MA68435A1 (https=)
MX (1) MX2024013281A (https=)
PE (1) PE20251064A1 (https=)
PY (1) PY2331055A (https=)
TW (1) TW202342751A (https=)
UY (1) UY40243A (https=)
WO (1) WO2023211315A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120365434A (zh) * 2024-01-23 2025-07-25 上海苹谱医疗科技有限公司 一种提高凝血因子ⅷ分泌水平的双信号肽及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2506868T1 (en) * 2009-12-06 2018-04-30 Bioverativ Therapeutics Inc. HYPER AND HYBRID POLYPETTIDES FACTOR VIII-FC AND METHODS FOR THEIR USE
EP2989208A4 (en) * 2013-04-22 2016-12-07 Catalent Pharma Solutions Llc DECORINAL COMPOSITIONS FOR VETERINARY MEDICINE AND USE THEREOF
RU2647769C2 (ru) * 2015-12-30 2018-03-19 Закрытое Акционерное Общество "Биокад" Химерный улучшенный рекомбинантный фактор VIII
CA3012695A1 (en) * 2016-02-01 2017-08-10 Bioverativ Therapeutics Inc. Optimized factor viii genes
US20220334124A1 (en) * 2019-09-03 2022-10-20 Sung Sub Kim Method for ultra-rapidly selecting signal peptide to which individual barcode system for increasing protein productivity is introduced
CN114929735A (zh) * 2019-11-01 2022-08-19 自由行疗法有限公司 因子viii构建体

Also Published As

Publication number Publication date
CO2024014703A2 (es) 2024-12-30
AU2023261711A1 (en) 2024-11-21
PE20251064A1 (es) 2025-04-09
EP4514975A1 (en) 2025-03-05
CN117402901A (zh) 2024-01-16
AR129164A1 (es) 2024-07-24
CA3250663A1 (en) 2023-11-02
CL2024003295A1 (es) 2025-02-21
TW202342751A (zh) 2023-11-01
WO2023211315A1 (en) 2023-11-02
CR20240525A (es) 2025-03-05
UY40243A (es) 2023-11-15
JP2025515356A (ja) 2025-05-14
MX2024013281A (es) 2024-12-06
IL316578A (en) 2024-12-01
PY2331055A (es) 2023-12-05
MA68435A1 (fr) 2025-04-30
KR20250005425A (ko) 2025-01-09

Similar Documents

Publication Publication Date Title
Lin et al. Osteopontin (OPN)/SPP1: from its biochemistry to biological functions in the innate immune system and the central nervous system (CNS)
Elster et al. Influenza virus M1 protein binds to RNA through its nuclear localization signal
WO2006014899A3 (en) Process for improved protein expression by strain engineering
BR0316435A (pt) Produtos genéticos expressos diferencialmente em tumores e uso dos mesmos
GB201201178D0 (en) Novel enzymes
Fox et al. Transcriptional regulation of secretory capacity by bZip transcription factors
JOP20240240A1 (ar) حمض نووي معزول يشفر بروتين اندماج قائم على fviii-bdd وعلى ببتيد إشارة غير متجانس
NZ609903A (en) Expression vector for high level expression of recombinant proteins
MX2021012671A (es) Métodos y materiales para la producción de proteínas.
Dudkina et al. New insight into secreted ribonuclease structure: binase is a natural dimer
JOP20230168A1 (ar) التأثير التآزري لـ SMN1 و miR-23a في علاج ضمور العضلات النخاعي
WO2022046935A3 (en) Methods and compositions for treating glioblastoma
JOP20220327A1 (ar) حمض نووي معزز بالكودون يشفَر بروتين smn1
EP4100534A4 (en) SYNTHETIC DNA CONSTRUCTS FOR REGULATING SIGNAL PEPTIDE PERFORMANCE AND VECTORS, HOST CELLS AND RECOMBINANT PROTEINS THEREOF
EA201690634A1 (ru) Новая гетеро-трансгликозилаза и ее применение
MX2020010652A (es) Genes asociados con resistencia a la roya amarilla del trigo.
JOP20240241A1 (ar) حمض نووي مُحسَّن بالكودون يشفر بروتين fviii-bdd
Li et al. Refinement of the Fusion Tag PagP for Effective Formation of Inclusion Bodies in Escherichia coli
NO20050338L (no) Nukleotidsekvenser som koder for torsingener torsinproteiner og fremgangsmater for anvendelse av det samme for behandling av proteinaggregering
ATE445009T1 (de) Signalpeptid zur herstellung eines polypeptids
Strzalka et al. Arabidopsi s thaliana: Proliferating cell nuclear antigen 1 and 2 possibly form homo-and hetero-trimeric complexes in the plant cell
WO2020188074A3 (en) Fatty acid synthase, inhibitors and modifications thereof and its use
ATE488592T1 (de) Auf antibiotikum basierendes genregulationssystem
Kurotani et al. Comprehensive bioinformatics analysis of cell‐free protein synthesis: identification of multiple protein properties that correlate with successful expression
ZA202308985B (en) Constructs and methods for increased expression of polypeptides